Member Info for BuenaVista

Hurst('you'll all be rich next week')10 just posts rampy drivel.

The only things he can see from his room in his mum's house TheGord is a wall and and a street.

Don't forget the third deal signing on Friday and IPO a week Tuesday HurstBot.

It's the secret MM signal that an RNS has been lodged.

Seriously, I don't think those low share number trades are done by PIs but rather by brokerages to collect their fees from investors.

AACR (American Association for Cancer Research)

ASCO (American Society of Clinical Oncology)

What new clinical data does Avacta have that could be presented at ASCO? None of any great significance.

CC and BH are likely to be in the US (Chicago) for ASCO. Doubtless the timings of the prelims have been influenced by the beginning and the end of ASCO.

Professor Eggy wrote: "after approaching 5 years of the ava6000 trial"

Truth is important. Surely a Professor should know that. The first patient was reported as dosed on 11 August 2021. That was 3 years 10 months ago, so approaching 4 years, not 5. I'm sure Professor Eggy would never try to deliberately deceive the board.

https://www.lse.co.uk/rns/AVCT/first-patient-dosed-in-ava6000-phase-1-trial-mvh7gownm99pq9f.html

Yes, the announcement also said that Phase 1a was anticipated to complete by Q2 2022 but that was Alan's - a novice at clinical trials with a company full of naive employees - ambitious timescale and, more importantly, they were expecting to find the Maximum Tolerated Dose, something which they never needed to find due to AVA6000's amazing Therapeutic Window.

Baillie Gifford Global Discovery Fund sold their Avacta holding in Q1 2025. Their rationale, as stated in their fund report dated 31 March 2025 was:

"We sold the holding in Avacta as recent clinical data of its targeted oncology drug (a tumour-released form of the longstanding chemotherapy drug doxorubicin) was underwhelming. While the better safety profile versus the existing standard of care was as predicted, this counts for very little if the efficacy falls below what was desired."

Note of course that this fund is NOT a specialist biopharma fund and that the AVA6000 Phase 1a study was a safety, tolerability and dose finding study, NOT an efficacy study!!!

The fund's performance over the past five years has been pretty dire - down 44.1%

https://www.hl.co.uk/funds/fund-discounts,-prices--and--factsheets/search-results/b/baillie-gifford-global-discovery-class-b-accumulation/charts

Compare to

Artemis US Smaller Companies over the same period - up 37.9%

https://www.hl.co.uk/funds/fund-discounts,-prices--and--factsheets/search-results/a/artemis-us-smaller-companies-class-i-accumulation/charts

AXA Framlington Global Technology - up 66.6%

https://www.hl.co.uk/funds/fund-discounts,-prices--and--factsheets/search-results/a/axa-framlington-global-technology-class-z-accumulation/charts

Even

AXA Framlington Biotech - up 2.6%

https://www.hl.co.uk/funds/fund-discounts,-prices--and--factsheets/search-results/a/axa-framlington-biotech-class-z-accumulation/charts

Toucanofdoom wrote: "What are the side effects of pembrolizumab and all the other non chemotherapy approaches to curing cancer?"

That's a very broad question. Let's keep it simple and on topic with something you could have done yourself if you really wanted to know and inform the board:

https://www.google.com/search?q=What+are+the+side+effects+of+pembrolizumab

Pembrolizumab (Keytruda) is an immunotherapy drug that can cause a variety of side effects, some of which are serious and can be life-threatening. These side effects are generally caused by the immune system being activated to fight the cancer, but sometimes overreacting. Common side effects include fatigue, rash, diarrhea, nausea, vomiting, and musculoskeletal pain. More serious side effects can include immune-mediated reactions affecting various organs, such as skin, lungs, thyroid, liver, kidneys, and nervous system.

Common Side Effects:

Fatigue: Feeling tired or weak.

Skin Reactions: Rash, itching, and sometimes more severe skin reactions like exfoliative dermatitis or Stevens-Johnson syndrome.

Gastrointestinal Issues: Diarrhea, nausea, vomiting, and in some cases, colitis (inflammation of the colon).

Musculoskeletal Pain: Muscle or joint pain.

Other: Decreased appetite, fever, cough, shortness of breath, and constipation.

Serious Side Effects:

Immune-Mediated Reactions: These can affect multiple organ systems, including:

Endocrine System: Thyroid problems (hypothyroidism or hyperthyroidism) and less commonly, adrenal insufficiency.

Skin: Severe skin reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

Lungs: Pneumonitis (inflammation of the lungs).

Liver: Hepatitis.

Kidneys: Nephritis (kidney inflammation) and kidney failure.

Nervous System: Encephalitis, Guillain-Barré syndrome, and other neurological problems.

Infusion-Related Reactions: Allergic reactions, including anaphylaxis.

Other Serious Reactions: Pancreatitis, hemolytic anemia, and other less common but serious reactions.

Managing Side Effects:

Report Symptoms:

It's crucial to report any new or worsening symptoms to your healthcare provider.

Symptom Management:

Treatment for side effects may include medications, supportive care, and adjustments to treatment plans.

Individualized Care:

The specific side effects and how they are managed can vary from person to person.

Important Considerations:

Variable Onset:

Immune-mediated reactions can develop weeks or even months after treatment has been stopped.

Severity: The severity of side effects can range from mild to life-threatening, requiring prompt medical attention.

Monitoring: Regular monitoring by your healthcare provider is important to detect and manage side effects effectively.

Question 1: Why do you call AVA6000 (FAP-Dox) 'old biotechnology' and do you regard AVA6103 (FAP-EXd) as 'old biotechnology' as well?

Toucanofdoom: "Because doxorubicin has been in use for years. OTOH the Precision platform is new technology."

My comment: So what if doxorubicin has been in use for years. It's use has been severely limited by cardiotoxicity and that means that no one has ever seen the full potential of doxorubicin that AVA6000, with its much, much lower toxicity, allows.

- - - - - - - -

Question 2: How do you know AVA6000 and/or AVA6103 and/or other pre|CISION substrates won't provide a cure in Phase 2/3?

Toucanofdoom: "AVA6000 delivers chemotherapy which isn’t a cure. Future Precision warheads could be. My point was that there are competing treatments out there."

My comment: As above, plus: chemotherapy CAN be a cure (Google 'Can chemotherapy be a cure'), even AVA6000 could be; secondly, there will always be other treatment options but their effectiveness vary according to type of cancer, stage of cancer, the patient's health, etc. (Google 'What determines a cancer treatment effectiveness')

- - - - - - - -

Question 3: You do know do you that pembrolizumab and FAP-warhead have totally different modes of action, so did it occur to you that a combination therapy could be super-effective?

Toucanofdoom: "Yes but it’s years off and pembrolizumab will be authorised long before then."

My comment: As above, plus: you neatly side-stepped the combination possibility (each component working synergistically with the others). Pembrolizumab is often used in combination therapies. The clue is in the over 1,600 ongoing trials - you don't need anything like that number for single therapy treatments.

- - - - - - - -

Question 4: Why do you think 'we aren’t getting any of the BP pie'?

Toucanofdoom: "Second half of your list I largely agree with."

My comment: Hooray. It's bleeding obvious that Avacta will need to acquire more funds by the end of this year and there are many possibilities as to how that can be achieved. It is up to each individual to decide how to play this - buy low now, wait for a lower entry point or wait for a fundraiser, which will only be a good move if the raise price is lower than the current or later lower share price.

I'm still waiting. Has the toucanofdoom expired? Is it pushing up daisies? Is it a late toucan? Well, clearly yes.

I have the Three Amigos - and various super-rampers and general idiots - on filter but do drop in to read comments if it's an interesting topic or, from what others write about them, they (the Amigos) are being particularly RC.

Open access copy: https://uk.finance.yahoo.com/news/china-latest-boom-sounding-alarm-070000754.html

"... However, drug companies are increasingly turning east when it comes to investing in new drugs and clinical trials. Not only is China becoming an easier place to research and create new drugs, but the Trump administration is also shaking faith in the US.

"Vaccine sceptic health secretary Robert F Kennedy Jr has prompted much anxiety in the industry. By contrast, China is “very business friendly and stable” Novartis boss Vas Narasimhan said in May. ..."

One thing I'd say about the quality of clinical trials carried out in China would be that due to genetic differences the biochemical pathways may be different. That has historically been Japan's (as the only major Asian market) reason for requiring clinical trials to also include cohorts of Japanese patients. However this is unlikely to affect Avacta's FAP tech as FAP is associated with cancer globally.

Toucanofdoom wrote (10:32): "I wasn’t saying pembrolizumab is better than AVA6000."

Toucanofdoom wrote (08:48): "The results from [Phase 3] trial of drugs like these are why BP are reticent to pump money into old biotechnology that only leads to remission rather than offering a potential cure."

Question 1: Why do you call AVA6000 (FAP-Dox) 'old biotechnology' and do you regard AVA6103 (FAP-EXd) as 'old biotechnology' as well?

AVA6000 has only so far been used in patients with stage 4 metastatic cancer, as is normal in Phase 1 trials. So...

Question 2: How do you know AVA6000 and/or AVA6103 and/or other pre|CISION substrates won't provide a cure in Phase 2/3?

Toucanofdoom wrote (10:32): "I was just giving an example of one of the competitors."

Question 3: You do know do you that pembrolizumab and FAP-warhead have totally different modes of action, so did it occur to you that a combination therapy could be super-effective?

Toucanofdoom wrote (10:32): "I look forward to your explanation as to why we aren’t getting any of the BP pie. Oh hold on it’s because they haven’t heard of us, or they’re as thick as mince etc etc"

I, personally have never said either of those things. As I used to work in pharma research information services I can guarantee that the pre|CISION tech was on the pharma industry radar as soon as the published AVA6000 patent application was indexed, abstracted and made publicly available and will have been followed ever more closely as the first preclinical and then clinical data appeared. I don't know why there haven't been any inked deals with big pharma yet. How could I or anyone not privy to inside information know? I have stated previously why I think there have been no deals yet, an expanded version of which is a combination of:

1) Statistically reliable data required.

2) Pharma is a very conservative industry that plays it very safe with very, very large sums of money. Thus the companies follow one another as a pack as few CEOs are prepared to go out on a limb with new tech UNTIL PROVEN. The dangers of getting it wrong are both personal, as in damage to reputation and removal from office, and company-wide, as in damage to reputation, reduced revenue and vulnerability to takeover.

3) Avacta know what they have and are not settling for anything less than what they think the drug candidates and tech are worth.

As regards, the share price, it is low for many reasons, several related to Avacta's past, but also the biopharma sector sentiment, the market as a whole, and the global economy.

Question 4: Why do you think 'we aren’t getting any of the BP pie'?

Undoubtedly they'll be attending to network and spread the word, any contributions would have been RNS'd.

Sunk costs..

There are numerous KEYNOTE trials studying KEYTRUDA (pembrolizumab) across various cancers and treatment settings, with Merck's clinical research program reporting over 1,600 ongoing trials. Some notable trials include KEYNOTE-189, KEYNOTE-407, KEYNOTE-042, and KEYNOTE-091, among others.

Key Points:

Extensive Research:

Merck has a large-scale program investigating KEYTRUDA across various cancers.

Diverse Trials:

Trials explore different cancer types, treatment settings, and biomarkers.

Specific Trials:

KEYNOTE-189, KEYNOTE-407, KEYNOTE-042, and KEYNOTE-091 are examples of trials that have been conducted.

Ongoing Research:

Merck continues to conduct and report on new trials, including phase 3 studies like KEYNOTE-867 and KEYNOTE-630, according to a Merck news release.

No, toucanofdoom, you are not. You are an imbecile.

From that BBC website article:

"The new approach showed positive results. It doubled the length of time patients were cancer free, on average, from around 2.5 years to five years.

"After three years, patients given pembrolizumab had a 10% lower risk of their cancer returning elsewhere in the body."

From the querying of Google with "Does pembrolizumab cure cancer":

Pembrolizumab (Keytruda) is an immunotherapy drug that helps the body's immune system fight cancer, but it's not a guaranteed cure for all cancers. It can shrink tumors, extend survival, and in some cases, even lead to complete remission, but it doesn't always eradicate the cancer entirely.

Here's a more detailed explanation:

How Pembrolizumab Works:

Pembrolizumab is a checkpoint inhibitor, meaning it blocks a protein (PD-1) that normally helps cancer cells hide from the immune system.

By blocking PD-1, pembrolizumab allows the immune system to attack and destroy cancer cells.

This can lead to tumor shrinkage, improved survival, and even in some cases, complete remission (where there is no evidence of cancer).

When Pembrolizumab is Used:

Pembrolizumab is used in various cancer types, including melanoma, lung cancer, cervical cancer, and some types of breast and bowel cancer.

It's often used in advanced or metastatic cancer, meaning the cancer has spread to other parts of the body.

It can also be used in conjunction with other treatments like chemotherapy.

Cure vs. Control:

While pembrolizumab can be very effective in shrinking tumors and prolonging life, it's not always a cure in the sense of completely eradicating the cancer.

In some cases, cancer may return after treatment with pembrolizumab.

The goal of treatment may shift from a cure to controlling the cancer, slowing its growth, and improving the patient's quality of life.

Factors Affecting Success:

The success of pembrolizumab depends on various factors, including the type of cancer, its stage, and the patient's overall health.

Some patients may experience a complete response to pembrolizumab, while others may not.

It's important to have realistic expectations and discuss the potential benefits and risks of treatment with your doctor.

Long-Term Outcomes:

Some studies have shown long-term survival benefits for patients treated with pembrolizumab, particularly in certain types of cancer.

The exact duration of remission or control can vary, and it's crucial to follow up with regular checkups and scans.

Research is ongoing to further understand the long-term effects of pembrolizumab and how to optimize its use in different cancer types.

"In addition to attacking journals, Kennedy expounded on some of his other favorite criticisms during the podcast, but with additional gusto.

""We're going to end the war at the FDA against alternative medicine, the war on stem cells or chelating drugs or peptides" or vitamins, he said. "Our position is that the FDA has a job to do the science ... and then tell the public what they've learned from the science but not tell people and not tell physicians what they can and cannot prescribe."

"If people want to take an experimental drug, "you shouldn't have to go to Antigua to get stem cells, which I had to do for my throat, right. And they helped me enormously."

"""Those industries, the pharmaceutical industry and the medical cartel, have transformed NIH, CDC, FDA, and CMS, which administers Medicaid and Medicare, into essentially sock puppets for the industry and profit centers," he said. "And they've commoditized the American public and turned us all into patients.""

Well I think it's your country's policy of corporate financing of political parties that has enabled that...

RFK Jr. is Trump and Project 2025's wrecking ball for the biomedical industry.

RFK Jr. May Ban NIH Scientists From Publishing in Top Medical Journals

https://www.medpagetoday.com/washington-watch/washington-watch/115794

"HHS will "probably" prevent NIH scientists from submitting their research to The Lancet, the New England Journal of Medicine, or JAMA because "they're all corrupt" due to pharmaceutical industry money, Secretary Robert F. Kennedy Jr. said Tuesday.

"Pharmaceutical funding holds scientists "hostages because they know what the outcome is and they write the outcome before they write the study," Kennedy said on "The Ultimate Human" podcast with Gary Brecka -- which ironically was frequently interrupted by pharma ads for Evenity, Entyvio, and several other products.

"He noted that some journal editors themselves have pointed out problems with pharmaceutical influence over the yearsopens in a new tab or window, including long-time and former New England Journal of Medicine editor Marcia Angell, MD, who Kennedy claimed criticized journals for becoming "a vessel for pharmaceutical propaganda. Because they control the journals."

"!

How is this a problem for NIH researchers? In Kennedy's mind, the 56,000 NIH grants handed out to researchers around the world -- some $46 billion in total, and most of them are in the U.S. -- "tend to be the people who have been approved by the industry. ... Part of an old boys network that knows what they can say and what they can't say."

"Kennedy also blasted the system by which the journals get paid. The pharmaceutical companies fund a study "that shows the outcome that they want, that statins work or that SSRIs work ... and they order reprints from the journal ... then give them to the pharmaceutical reps," he said. "Hot-looking girls or hot-looking guys go to the doctor's office, take them to lunch and give them the reprint to say this product works."

"Instead of continuing this "corrupt" system, HHS will "create our own journals in-house ... [and] they will become the prominent journals," he said.

"That's a move that some of Kennedy's direct reports have been involved with before. NIH Director Jay Bhattacharya, MD, PhD, and FDA Commissioner Marty Makary, MD, MPH, were both involved in the creation of the Journal of the Academy of Public Healthopens in a new tab or window, which they billed as an alternative to traditional publishing.

"James Lawler, MD, MPH, an infectious diseases expert at the University of Nebraska Medical Center's Global Center for Health Security, made a quip about Kennedy's HHS journal: "If we couldn't get any more Ministry-of-Truth-ish, now we have," he said. "If you wanted to instantiate '1984' into real life, this is it."

"In response to Kennedy's comments, the NEJM said in a statement that it is "one of the most trusted medical journals, with an impeccable record of scientific rigor and independence. We use rigorous peer review and editorial processes [continues]

America, land of the fee, will have nothing to do with the Socialism of a publicly funded healthcare system like the NHS with it's 'death panels'.